You are here

  • Home
  • Archive
  • Volume 8, Issue 2
  • Correction: Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study

Article Text

Article menu

See original article:

Download PDFPDF

XML
Correction
Correction: Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study

https://doi.org/10.1136/jitc-2019-000437corr1

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Shen L, Guo J, Zhang Q, et al. Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study. J immunother Cancer 2020;8:e000437. doi: 10.1136/jitc-2019-000437

    Since the online publication of this article, the authors have noticed that the author name Zuobai Wang was incorrectly spelt as Zoubai Wang. This has been corrected.